Abstract
We describe the discovery of UNC1215, a potent and selective chemical probe for the methyllysine (Kme) reading function of L3MBTL3, a member of the malignant brain tumor (MBT) family of chromatin-interacting transcriptional repressors. UNC1215 binds L3MBTL3 with a Kd of 120 nM, competitively displacing mono- or dimethyllysine-containing peptides, and is greater than 50-fold more potent toward L3MBTL3 than other members of the MBT family while also demonstrating selectivity against more than 200 other reader domains examined. X-ray crystallography identified a unique 2:2 polyvalent mode of interaction between UNC1215 and L3MBTL3. In cells, UNC1215 is nontoxic and directly binds L3MBTL3 via the Kme-binding pocket of the MBT domains. UNC1215 increases the cellular mobility of GFP-L3MBTL3 fusion proteins, and point mutants that disrupt the Kme-binding function of GFP-L3MBTL3 phenocopy the effects of UNC1215 on localization. Finally, UNC1215 was used to reveal a new Kme-dependent interaction of L3MBTL3 with BCLAF1, a protein implicated in DNA damage repair and apoptosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wang, Z. et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 40, 897–903 (2008).
Taverna, S.D., Li, H., Ruthenburg, A.J., Allis, C.D. & Patel, D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14, 1025–1040 (2007).
Hughes, R.M., Wiggins, K.R., Khorasanizadeh, S. & Waters, M.L. Recognition of trimethyllysine by a chromodomain is not driven by the hydrophobic effect. Proc. Natl. Acad. Sci. USA 104, 11184–11188 (2007).
Zacharias, N. & Dougherty, D.A. Cation-π interactions in ligand recognition and catalysis. Trends Pharmacol. Sci. 23, 281–287 (2002).
Dawson, M.A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011).
Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-myc. Cell 146, 904–917 (2011).
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
Zeng, L. et al. Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b. Nature 466, 258–262 (2010).
Margueron, R. et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762–767 (2009).
Adams-Cioaba, M.A. & Min, J. Structure and function of histone methylation binding proteins. Biochem. Cell Biol. 87, 93–105 (2009).
Kuo, A.J. et al. The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome. Nature 484, 115–119 (2012).
Li, H. et al. Structural basis for lower lysine methylation state–specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. Mol. Cell 28, 677–691 (2007).
Santiago, C., Nguyen, K. & Schapira, M. Druggability of methyl-lysine binding sites. J. Comput. Aided Mol. Des. 25, 1171–1178 (2011).
Herold, J.M. et al. Structure-activity relationships of methyl-lysine reader antagonists. Med. Chem. Commun. 3, 45–51 (2012).
Herold, J.M. et al. Small-molecule ligands of methyl-lysine binding proteins. J. Med. Chem. 54, 2504–2511 (2011).
Frye, S.V. The art of the chemical probe. Nat. Chem. Biol. 6, 159–161 (2010).
Bonasio, R., Lecona, E. & Reinberg, D. MBT domain proteins in development and disease. Semin. Cell Dev. Biol. 21, 221–230 (2010).
Addou-Klouche, L. et al. Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol. Cancer 9, 213 (2010).
Northcott, P.A. et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat. Genet. 41, 465–472 (2009).
Gurvich, N. et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc. Natl. Acad. Sci. USA 107, 22552–22557 (2010).
Perna, F. et al. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood 116, 2812–2821 (2010).
Honda, H. et al. Hemp, an MBT domain–containing protein, plays essential roles in hematopoietic stem cell function and skeletal formation. Proc. Natl. Acad. Sci. USA 108, 2468–2473 (2011).
Arai, S. & Miyazaki, T. Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1. EMBO J. 24, 1863–1873 (2005).
Nady, N. et al. Histone recognition by human malignant brain tumor domains. J. Mol. Biol. 423, 702–718 (2012).
Bonasio, R., Lecona, E. & Reinberg, D. MBT domain proteins in development and disease. Semin. Cell Dev. Biol. 21, 221–230 (2010).
Botuyan, M.V. et al. Structural basis for the methylation state–specific recognition of histone H4–K20 by 53BP1 and Crb2 in DNA repair. Cell 127, 1361–1373 (2006).
Wigle, T.J. et al. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreenTM-based assay for antagonists of methyl-lysine binding proteins. J. Biomol. Screen. 15, 62–71 (2010).
Gao, C. et al. Biophysical probes reveal a “compromise” nature of the methyl-lysine binding pocket in L3MBTL1. J. Am. Chem. Soc. 133, 5357–5362 (2011).
Nady, N. et al. Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein. J. Biol. Chem. 286, 24300–24311 (2011).
Wang, W.K. et al. Malignant brain tumor repeats: a three-leaved propeller architecture with ligand/peptide binding pockets. Structure 11, 775–789 (2003).
Kim, J. et al. Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep. 7, 397–403 (2006).
Takada, Y. et al. Mammalian polycomb Scmh1 mediates exclusion of polycomb complexes from the XY body in the pachytene spermatocytes. Development 134, 579–590 (2007).
Trojer, P. et al. L3MBTL2 protein acts in concert with PcG protein–mediated monoubiquitination of H2A to establish a repressive chromatin structure. Mol. Cell 42, 438–450 (2011).
Trojer, P. et al. L3MBTL1, a histone-methylation–dependent chromatin lock. Cell 129, 915–928 (2007).
Ogawa, H., Ishiguro, K.-I., Gaubatz, S., Livingston, D.M. & Nakatani, Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 296, 1132–1136 (2002).
Nady, N. et al. Histone recognition by human malignant brain tumor domains. J. Mol. Biol. 423, 702–718 (2012).
Kim, C.A., Gingery, M., Pilpa, R.M. & Bowie, J.U. The SAM domain of polyhomeotic forms a helical polymer. Nat. Struct. Biol. 9, 453–457 (2002).
Knight, M.J., Leettola, C., Gingery, M., Li, H. & Bowie, J.U. A human sterile α motif domain polymerizome. Protein Sci. 20, 1697–1706 (2011).
Haraguchi, T. et al. Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy. Eur. J. Biochem. 271, 1035–1045 (2004).
Lee, Y.Y., Yu, Y.B., Gunawardena, H.P., Xie, L. & Chen, X. BCLAF1 is a radiation-induced H2AX-interacting partner involved in γH2AX-mediated regulation of apoptosis and DNA repair. Cell Death Dis. 3, e359 (2012).
Hope, H. Cryocrystallography of biological macromolecules: a generally applicable method, Acta Crystallogr. B 44, 22–26 (1988).
Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
Evans, P.R. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr. D Biol. Crystallogr. 67, 282–292 (2011).
Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 (2006).
McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658–674 (2007).
Berman, H.M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235–242 (2000).
Schüttelkopf, A.W. & van Aalten, D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355–1363 (2004).
Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).
Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).
Yguerabide, J., Schmidt, J.A. & Yguerabide, E.E. Lateral mobility in membranes as detected by fluorescence recovery after photobleaching. Biophys. J. 40, 69–75 (1982).
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
Acknowledgements
We thank M. Vedadi, G. Wasney and F. Li for support with the protein lysine methyltransferase selectivity screening; O. Fedorov for support with the bromodomain selectivity screening; A. Tumber for support with the lysine demethylase selectivity screening; E. Hull-Ryde for support with the CellTiter-Glo cell viability assay; K. Hahn (University of North Carolina (UNC)) for providing mero76; B. Roth for helpful discussion regarding the GPCR selectivity studies; and G. Wang (UNC) for providing PHF23 and JARID1 proteins. Results shown in this report are derived from work performed at the Structural Biology Center at the Advanced Photon Source at Argonne National Laboratory. Argonne is operated by UChicago Argonne, LLC, for the US Department of Energy, Office of Biological and Environmental Research, under contract DE-AC02-06CH11357. The research described here was supported by the US National Institute of General Medical Sciences; US National Institutes of Health (grant RC1GM090732 and R01GM100919); the Carolina Partnership and the University Cancer Research Fund; University of North Carolina at Chapel Hill; the Center for Environmental and Molecular Carcinogenesis at the M.D. Anderson Cancer Center; the National Institute of Mental Health Psychoactive Drug Screening Program; the Ontario Research Fund (grant ORF-GL2); the Natural Sciences and Engineering Research Council of Canada; the Ontario Ministry of Health and Long-Term Care; the American Cancer Society (C.J.M.; 119169-PF-10-183-01-TBE); and the Structural Genomics Consortium, which is a registered charity (number 1097737) that receives funds from Canadian Institutes of Health Research; Eli Lilly Canada; Genome Canada; GlaxoSmithKline; the Ontario Ministry of Economic Development and Innovation; the Novartis Research Foundation; Pfizer; Abbott; Takeda; and the Wellcome Trust. M.T.B. is supported by an institutional grant from the US National Institute of Environmental Health Sciences (ES007784) and Cancer Prevention Research Institute of Texas funding (RP110471). C.H.A. holds a Canada Research Chair in Structural Genomics.
Author information
Authors and Affiliations
Contributions
L.I.J. synthesized all compounds and related analogs and performed ITC studies; D.B.-L. and L.K. performed immunofluorescence FRAP, affinity purification and coimmunoprecipitation studies; N.Z. and W.T. solved and analyzed the X-ray crystal structure of the UNC1215–L3MBTL3 complex; V.K.K. and W.P.J. performed and analyzed AlphaScreen studies; C.J.M. synthesized the mero76-UNC1215 conjugate; J.L.N. purified proteins and performed mutagenesis; C.A.S. and M.T.B. performed protein array and protein pull-down experiments; E.M., H.G., A.E. and J.F.G. performed MS-based studies; S.D. cloned mammalian expression vectors for all cellular studies; X.-P.H. performed and analyzed GPCR selectivity studies; L.I.J., D.B.-L., N.Z., L.K., J.M.H., V.K.K., C.G., D.B.K., J.J., W.P.J., P.J.B., M.T.B, C.H.A. and S.V.F. designed studies and discussed results; L.I.J., C.H.A. and S.V.F. wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Methods and Supplementary Results (PDF 4334 kb)
Supplementary Note 1
SuppNote_final.pdf (PDF 795 kb)
Rights and permissions
About this article
Cite this article
James, L., Barsyte-Lovejoy, D., Zhong, N. et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 9, 184–191 (2013). https://doi.org/10.1038/nchembio.1157
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1157
This article is cited by
-
An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering
Nature Communications (2023)
-
A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization
Nature Chemical Biology (2022)
-
Targeting non-bromodomain chromatin readers
Nature Structural & Molecular Biology (2019)
-
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Nature Medicine (2019)
-
Targeting protein methylation: from chemical tools to precision medicines
Cellular and Molecular Life Sciences (2019)